Inhibition of CaMKII by either pharmacological or genetic approaches reverses heart failure–associated changes (i.e., arrhythmias, hypertrophy, and dysfunction) in animal models of structural heart disease [5], [6]. This evidence concerns the gene CAMK2G and heart failure.